Business Description
Janux Therapeutics is a San Diego-based clinical-stage company working to develop next-generation cancer treatments that harness the body's immune system to target tumors more precisely. Its lead drug candidates are currently in Phase 1 trials targeting prostate cancer, a range of solid tumors, and certain autoimmune diseases. The company works alongside major pharmaceutical partners Merck and Bristol Myers Squibb to advance its pipeline. Founded in 2017, Janux continues to build on its proprietary technology platforms to improve outcomes for patients with difficult-to-treat cancers.
